H. Lundbeck A/S has closed a deal for Chelsea Therapeutics International Ltd.

Chelsea, headquartered in Deerfield, Ill., develops therapy products, including Northera. The medicine, which treats lightheadedness in patients with low blood pressure, was  approved by the U.S. Food and Drug Administration earlier this year.

Lundbeck is a Copenhagen-based pharmaceutical company that specializes in brain diseases, including alcohol dependence, Alzheimer's disease, depression, epilepsy, Huntington's disease, Parkinson's disease, schizophrenia and stroke. 

The company plans to make Northera available in the U.S. in fall 2014.

Other recent pharmaceutical deals include Merck's agreement to buy Idenix Pharmaceuticals, which is developing hepatitis C treatments, for $3.85 billion, and Shire plc's $260 million deal for Lumena, which develops liver disease treatments. 

 

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.